Save a life today, save thousands tomorrow
The Royal Marsden Cancer Charity is supporting the development of new treatments that will help to save the lives of cancer patients everywhere. For friends, for family, for the future.
Jenny’s story shows us what’s possible
At 37, Jenny from Portsmouth faced a life-changing diagnosis: advanced melanoma. In 2024, Jenny was told that her cancer had spread and was inoperable. She was offered the chance to join a clinical trial called TILVANCE-301. Thanks to this groundbreaking trial, the tumour has begun to shrink and Jenny is now living life to the full with her family.
"The trial is fantastic and is saving my life."
What is the TILVANCE-301 trial?
Jenny joined the TILVANCE-301 clinical trial which tests the benefits for melanoma patients of using a combination of cancer immunotherapy treatments. Immunotherapy harnesses the patient's own immune cells to attack and destroy cancer cells. This trial explores using lifileucel, a type of immunotherapy called TIL therapy, alongside a drug called pembrolizumab.
Watch Jenny and Research Advanced Nurse Practitioner, Lauren, talk about the trial as part of our candid conversations about cancer series.
The work we support saves the lives of thousands of people like Jenny every year.
Help us to make groundbreaking developments in research and treatment for cancer patients everywhere.With cancer rates set to rise 40% by 2050*, we need breakthroughs more than ever before.
*Source: JAMA Oncology estimates a 41.7% rise in very high–HDI countries and IARC/WHO data show a predicted 37% increase in the UK.